Proteomic-Based Biosignatures in Breast Cancer Classification and Prediction of Therapeutic Response

Gonda/UCLA Breast Cancer Research Laboratory, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.
International journal of proteomics 10/2011; 2011(2090-2166):896476. DOI: 10.1155/2011/896476
Source: PubMed


Protein-based markers that classify tumor subtypes and predict therapeutic response would be clinically useful in guiding patient treatment. We investigated the LC-MS/MS-identified protein biosignatures in 39 baseline breast cancer specimens including 28 HER2-positive and 11 triple-negative (TNBC) tumors. Twenty proteins were found to correctly classify all HER2 positive and 7 of the 11 TNBC tumors. Among them, galectin-3-binding protein and ALDH1A1 were found preferentially elevated in TNBC, whereas CK19, transferrin, transketolase, and thymosin β4 and β10 were elevated in HER2-positive cancers. In addition, several proteins such as enolase, vimentin, peroxiredoxin 5, Hsp 70, periostin precursor, RhoA, cathepsin D preproprotein, and annexin 1 were found to be associated with the tumor responses to treatment within each subtype. The MS-based proteomic findings appear promising in guiding tumor classification and predicting response. When sufficiently validated, some of these candidate protein markers could have great potential in improving breast cancer treatment.

Download full-text


Available from: Julian Philip Whitelegge
  • [Show abstract] [Hide abstract]
    ABSTRACT: Annexin A1 (ANXA1) is a protein related with the carcinogenesis process and metastasis formation in many tumors. However, little is known about the prognostic value of ANXA1 in breast cancer. The purpose of this study is to evaluate the association between ANXA1 expression, BRCA1/2 germline carriership, specific tumor subtypes and survival in breast cancer patients. Clinical-pathological information and follow-up data were collected from nine breast cancer studies from the Breast Cancer Association Consortium (BCAC) (n = 5,752) and from one study of familial breast cancer patients with BRCA1/2 mutations (n = 107). ANXA1 expression was scored based on the percentage of immunohistochemical staining in tumor cells. Survival analyses were performed using a multivariable Cox model. The frequency of ANXA1 positive tumors was higher in familial breast cancer patients with BRCA1/2 mutations than in BCAC patients, with 48.6 % versus 12.4 %, respectively; P <0.0001. ANXA1 was also highly expressed in BCAC tumors that were poorly differentiated, triple negative, EGFR-CK5/6 positive or had developed in patients at a young age. In the first 5 years of follow-up, patients with ANXA1 positive tumors had a worse breast cancer-specific survival (BCSS) than ANXA1 negative (HRadj = 1.35; 95 % CI = 1.05-1.73), but the association weakened after 10 years (HRadj = 1.13; 95 % CI = 0.91-1.40). ANXA1 was a significant independent predictor of survival in HER2+ patients (10-years BCSS: HRadj = 1.70; 95 % CI = 1.17-2.45). ANXA1 is overexpressed in familial breast cancer patients with BRCA1/2 mutations and correlated with poor prognosis features: triple negative and poorly differentiated tumors. ANXA1 might be a biomarker candidate for breast cancer survival prediction in high risk groups such as HER2+ cases.
    No preview · Article · Jul 2015 · BMC Medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone and soft tissue sarcomas are a diverse group of malignancies derived from mesenchymal tissue. Numerous different sub-types of sarcoma can be identified histologically and this reflects the capacity of mesenchymal precursor cells to differentiate along recognisable somatic lineages, although some sarcomas do not display any clear line of differentiation and form tumours with no obvious normal cellular counterpart. The morphological heterogeneity of sarcomas is paralleled by differences in biological behaviour that contribute to difficulties in understanding tumour progression and patterns of response to treatment. Although five-year survival rates of up to 80% can be achieved for localised sarcomas, some specific high-grade histological subtypes continue to portent poor prognosis, and metastasis at presentation remains a common problem. Identifying in advance the chemosensitivity of primary sarcomas, those sarcomas destined to metastasise, and successfully treating metastatic disease continues to pose a significant challenge. Proteomic analysis combined with mass spectroscopy and bioinformatics is a powerful approach to analysing molecular abnormalities responsible for the biological behaviour of sarcomas. Investigating abnormalities downstream of the genome using protein expression analysis has several important advantages over DNA sequencing or mRNA expression studies in cancer research. Sophisticated proteomic technologies have only recently been applied to the study of sarcomas with the principle aim of discovering new disease-specific biomarkers that will facilitate more accurate classification of sarcomas into clinically relevant sub-types as well as identifying novel therapeutic targets. This article will review recent developments and summarise the emerging role of proteomic analysis in the strategy of applying molecular classification to both the diagnosis and targeted treatment of sarcomas.
    No preview · Article · May 2012 · Current Proteomics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer contains a small population of cancer stem cells that contribute to its initiation and progression. We investigated the biological function and clinical significance of aldehyde dehydrogenase 1A1 (ALDH1A1) in non-small-cell lung carcinoma (NSCLC). ALDH1A1 assay or small interfering RNA transfection was employed to isolate ALDH1A1+ cells or knock down ALDH1A1 expression in H2087 cells, respectively. Biological functions of ALDH1A1+ and ALDH1A1 silenced cells were investigated using in vitro and in vivo methods. ALDH1A1 expression was analyzed using immunohistochemistry on tissue microarrays with 179 lung cancer tissues and 26 normal lung tissues. The abilities of clone formation, proliferation, cell growth, and migration were increased in ALDH1A1+ and ALDH1A1 silenced cells. ALDH1A1+ lung cancer cells initiated tumors that resembled the histopathologic characteristics and heterogeneity of the parental lung cancer cells in mice. The silencing of ALDH1A1 expression in H2087 lung cancer cells inhibited cell proliferation and migration significantly. ALDH1A1 was expressed in 42% of normal lung tissues (11 of 26), with strong expression in the basal cells and globular cells of the normal bronchus and weak expression in the alveolar epithelial cells. Compared with normal lung tissues, 45% of NSCLC samples (81 of 179) were read as positive for ALDH1A1. Positive ALDH1A1 expression was correlated with patients' smoking status (p = 0.022), lymph-node metastasis (p = 0.006), clinical stage (p = 0.004), and a decreased overall survival time (p < 0.001). Positive ALDH1A1 expression in lung cancer tissues was an independent prognostic factor for NSCLC (odds ratio = 5.232, p < 0.001). Elucidating the biological functions of ALDH1A1 could be helpful in studying lung tumorigenesis and for developing new therapeutic approaches.
    No preview · Article · May 2012 · Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer
Show more